Risk of venous and arterial thromboembolic events in women with advanced breast cancer treated with CDK 4/6 inhibitors: A systematic review and meta-analysis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Risk of venous and arterial thromboembolic events in women with advanced breast cancer treated with CDK 4/6 inhibitors: A systematic review and meta-analysis
Authors
Keywords
Breast cancer, CDK 4/6 inhibitors, Arterial thromboembolism, Venous thromboembolism
Journal
THROMBOSIS RESEARCH
Volume 208, Issue -, Pages 190-197
Publisher
Elsevier BV
Online
2021-11-17
DOI
10.1016/j.thromres.2021.11.009
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real‐world practice
- (2021) Malinda T. West et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
- (2021) D.J. Slamon et al. ANNALS OF ONCOLOGY
- Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
- (2019) Seock-Ah Im et al. NEW ENGLAND JOURNAL OF MEDICINE
- Arterial Thrombosis in Cancer: Spotlight on the Neglected Vessels
- (2019) MARIA LAURA CANALE et al. ANTICANCER RESEARCH
- Venous thromboembolism in breast cancer patients receiving cyclin‐dependent kinase inhibitors
- (2019) Lorenzo Gervaso et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
- (2019) George W. Sledge et al. JAMA Oncology
- Breast cancer statistics, 2019
- (2019) Carol E. DeSantis et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
- (2019) Dennis J. Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
- (2018) G N Hortobagyi et al. ANNALS OF ONCOLOGY
- 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†
- (2018) F Cardoso et al. ANNALS OF ONCOLOGY
- Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3
- (2018) Dennis J. Slamon et al. JOURNAL OF CLINICAL ONCOLOGY
- Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
- (2018) Debu Tripathy et al. LANCET ONCOLOGY
- A Real-World Experience of Palbociclib-Induced Adverse Events and Compliance with Complete Blood Count (CBC) Monitoring in Women with Hormone Receptor (HR) -Positive/Her2-Negative Metastatic Breast Cancer
- (2018) G.A. Watson et al. Clinical Breast Cancer
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
- (2018) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cyclin-Dependent Kinase Inhibitor–Associated Thromboembolism
- (2018) Sven R. Olson et al. JAMA Oncology
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- (2017) George W. Sledge et al. JOURNAL OF CLINICAL ONCOLOGY
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- New findings on venous thrombogenesis
- (2016) J. R. Byrnes et al. Hamostaseologie
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- (2016) Massimo Cristofanilli et al. LANCET ONCOLOGY
- Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
- (2016) P. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Treating cancer with selective CDK4/6 inhibitors
- (2016) Ben O'Leary et al. Nature Reviews Clinical Oncology
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term arterial complications of chemotherapy in patients with cancer
- (2016) Tone Svilaas et al. THROMBOSIS RESEARCH
- Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies
- (2015) W. Hu et al. CLINICAL CANCER RESEARCH
- Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State
- (2015) Betsy A. Kohler et al. JNCI-Journal of the National Cancer Institute
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State
- (2015) Betsy A. Kohler et al. JNCI-Journal of the National Cancer Institute
- Under-reporting of venous and arterial thrombotic events in randomized clinical trials: a meta-analysis
- (2014) Danka J. F. Stuijver et al. Internal and Emergency Medicine
- Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective
- (2014) Roelof W F van Leeuwen et al. LANCET ONCOLOGY
- Epidemiology of cancer-associated venous thrombosis
- (2013) J. F. Timp et al. BLOOD
- Breast cancer as a systemic disease: a view of metastasis
- (2013) A. J. Redig et al. JOURNAL OF INTERNAL MEDICINE
- ER -Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer
- (2011) T. W. Miller et al. Cancer Discovery
- Mechanisms of Endocrine Resistance in Breast Cancer
- (2010) C. Kent Osborne et al. Annual Review of Medicine
- Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition
- (2010) Søren M. Johnson et al. JOURNAL OF CLINICAL INVESTIGATION
- Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients
- (2008) Shobha Rani Nalluri et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search